Cooper Companies (NYSE:COO – Get Rating) had its price target reduced by equities researchers at KeyCorp from $459.00 to $414.00 in a report issued on Wednesday, The Fly reports. The brokerage presently has an “overweight” rating on the medical device company’s stock. KeyCorp’s price objective points to a potential upside of 21.39% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Wells Fargo & Company reduced their target price on shares of Cooper Companies from $495.00 to $380.00 and set an “overweight” rating for the company in a research report on Monday. Citigroup upgraded Cooper Companies from a “neutral” rating to a “buy” rating and lowered their target price for the stock from $460.00 to $405.00 in a report on Tuesday, May 17th. StockNews.com initiated coverage on Cooper Companies in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Piper Sandler upped their target price on Cooper Companies from $490.00 to $500.00 in a report on Friday, March 4th. Finally, Stephens lifted their price target on Cooper Companies from $430.00 to $500.00 and gave the stock an “overweight” rating in a report on Monday, March 7th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Cooper Companies currently has an average rating of “Buy” and an average target price of $452.78.
COO stock opened at $341.05 on Wednesday. Cooper Companies has a 52 week low of $309.43 and a 52 week high of $463.59. The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt-to-equity ratio of 0.34. The firm has a 50-day simple moving average of $382.90 and a 200-day simple moving average of $395.10. The stock has a market capitalization of $16.81 billion, a P/E ratio of 18.09, a P/E/G ratio of 2.19 and a beta of 0.90.
In related news, Director Jody S. Lindell sold 700 shares of Cooper Companies stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $421.04, for a total value of $294,728.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert S. Weiss sold 13,039 shares of the stock in a transaction that occurred on Tuesday, March 29th. The stock was sold at an average price of $415.24, for a total transaction of $5,414,314.36. The disclosure for this sale can be found here. Insiders sold a total of 19,646 shares of company stock worth $8,195,614 over the last three months. Insiders own 1.70% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Riverview Trust Co acquired a new position in Cooper Companies during the 1st quarter worth $29,000. Liberty Wealth Management LLC lifted its stake in Cooper Companies by 1,340.0% in the third quarter. Liberty Wealth Management LLC now owns 72 shares of the medical device company’s stock worth $30,000 after acquiring an additional 67 shares during the last quarter. PrairieView Partners LLC acquired a new position in Cooper Companies during the 4th quarter worth approximately $33,000. O Shaughnessy Asset Management LLC increased its position in shares of Cooper Companies by 66.7% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 85 shares of the medical device company’s stock valued at $35,000 after purchasing an additional 34 shares during the last quarter. Finally, Trust Co. of Vermont acquired a new stake in shares of Cooper Companies in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 98.38% of the company’s stock.
Cooper Companies Company Profile (Get Rating)
The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific.
- Get a free copy of the StockNews.com research report on Cooper Companies (COO)
- Two Retailers, One To Buy And One To Avoid
- Indie Semiconductor Stock is Putting in a Bottom
- Investors Can Get 5%-Plus Dividend Yields on These 3 Buys
- It’s Time to Buy into Planet Fitness Stock
- 3 Defensive Consumer Stocks Worth Shopping For
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.